» Articles » PMID: 1381276

Inhibition of Angiogenesis by Suramin

Overview
Journal Cancer Res
Specialty Oncology
Date 1992 Sep 15
PMID 1381276
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

In this study, we have determined the ability of suramin to inhibit angiogenesis in the chick chorioallantoic membrane. Suramin alone showed significant angiostatic activity in a dose-related manner. Suramin also potentiated the activity of the angiostatic steroids, cortisol-21-phosphate, 17 alpha-hydroxyprogesterone, tetrahydrocortisol, and tetrahydrocortexolone. The presence of heparin decreased the angiostatic activity of suramin. These results suggest that suramin may decrease tumor growth by inhibiting angiogenesis. These novel findings indicate that suramin, perhaps in combination with angiostatic steroids, may be the basis for important new therapeutic approaches for diseases of neovascularization.

Citing Articles

In Vitro Angiogenesis Inhibition and Endothelial Cell Growth and Morphology.

Ljoki A, Aslam T, Friis T, Ohm R, Houen G Int J Mol Sci. 2022; 23(8).

PMID: 35457095 PMC: 9025250. DOI: 10.3390/ijms23084277.


An Avant-Garde Model of Injury-Induced Regenerative Vaginal Wound Healing.

McCracken J, Balaji S, Keswani S, Hakim J Adv Wound Care (New Rochelle). 2020; 10(4):165-173.

PMID: 32602816 PMC: 7906868. DOI: 10.1089/wound.2020.1198.


Heparin Binding Proteins as Therapeutic Target: An Historical Account and Current Trends.

Ghiselli G Medicines (Basel). 2019; 6(3).

PMID: 31362364 PMC: 6789896. DOI: 10.3390/medicines6030080.


Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.

Ling L, Tan S, Goh T, Cheung E, Nurcombe V, van Wijnen A Mol Cancer. 2015; 14:136.

PMID: 26201468 PMC: 4511971. DOI: 10.1186/s12943-015-0391-4.


A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.

Palmer G, Tiran Z, Zhou Z, Capozzi M, Park W, Coletta C Br J Pharmacol. 2011; 165(6):1891-1903.

PMID: 21943108 PMC: 3372838. DOI: 10.1111/j.1476-5381.2011.01677.x.